BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 26153859)

  • 1. Progesterone receptor modulates ERα action in breast cancer.
    Mohammed H; Russell IA; Stark R; Rueda OM; Hickey TE; Tarulli GA; Serandour AA; Birrell SN; Bruna A; Saadi A; Menon S; Hadfield J; Pugh M; Raj GV; Brown GD; D'Santos C; Robinson JL; Silva G; Launchbury R; Perou CM; Stingl J; Caldas C; Tilley WD; Carroll JS
    Nature; 2015 Jul; 523(7560):313-7. PubMed ID: 26153859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
    Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
    Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes.
    Diep CH; Ahrendt H; Lange CA
    Steroids; 2016 Oct; 114():48-58. PubMed ID: 27641443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
    Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
    Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
    Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
    J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERα-36 regulates progesterone receptor activity in breast cancer.
    Konan HP; Kassem L; Omarjee S; Surmieliova-Garnès A; Jacquemetton J; Cascales E; Rezza A; Trédan O; Treilleux I; Poulard C; Le Romancer M
    Breast Cancer Res; 2020 May; 22(1):50. PubMed ID: 32429997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer.
    Yu S; Kim T; Yoo KH; Kang K
    Biochem Biophys Res Commun; 2017 May; 486(3):752-758. PubMed ID: 28342866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells.
    Mao C; Patterson NM; Cherian MT; Aninye IO; Zhang C; Montoya JB; Cheng J; Putt KS; Hergenrother PJ; Wilson EM; Nardulli AM; Nordeen SK; Shapiro DJ
    J Biol Chem; 2008 May; 283(19):12819-30. PubMed ID: 18337247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.
    Sundar SN; Marconett CN; Doan VB; Willoughby JA; Firestone GL
    Carcinogenesis; 2008 Dec; 29(12):2252-8. PubMed ID: 18784357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
    Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
    Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
    Severson TM; Nevedomskaya E; Peeters J; Kuilman T; Krijgsman O; van Rossum A; Droog M; Kim Y; Koornstra R; Beumer I; Glas AM; Peeper D; Wesseling J; Simon IM; Wessels L; Linn SC; Zwart W
    Oncotarget; 2016 Jun; 7(23):33901-18. PubMed ID: 27129152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter.
    De Amicis F; Zupo S; Panno ML; Malivindi R; Giordano F; Barone I; Mauro L; Fuqua SA; Andò S
    Mol Endocrinol; 2009 Apr; 23(4):454-65. PubMed ID: 19147702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.
    Schultz DJ; Wickramasinghe NS; Ivanova MM; Isaacs SM; Dougherty SM; Imbert-Fernandez Y; Cunningham AR; Chen C; Klinge CM
    Mol Cancer Ther; 2010 Mar; 9(3):594-605. PubMed ID: 20197399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation.
    Pedroza DA; Subramani R; Tiula K; Do A; Rashiraj N; Galvez A; Chatterjee A; Bencomo A; Rivera S; Lakshmanaswamy R
    Lab Invest; 2021 Jun; 101(6):733-744. PubMed ID: 33903732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.
    Wortham NC; Ahamed E; Nicol SM; Thomas RS; Periyasamy M; Jiang J; Ochocka AM; Shousha S; Huson L; Bray SE; Coombes RC; Ali S; Fuller-Pace FV
    Oncogene; 2009 Nov; 28(46):4053-64. PubMed ID: 19718048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells.
    Won Jeong K; Chodankar R; Purcell DJ; Bittencourt D; Stallcup MR
    Mol Endocrinol; 2012 Jun; 26(6):955-66. PubMed ID: 22543272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.
    Irish JC; Mills JN; Turner-Ivey B; Wilson RC; Guest ST; Rutkovsky A; Dombkowski A; Kappler CS; Hardiman G; Ethier SP
    Mol Oncol; 2016 Jun; 10(6):850-65. PubMed ID: 27005559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.
    Karmakar S; Gao T; Pace MC; Oesterreich S; Smith CL
    Mol Endocrinol; 2010 Jun; 24(6):1187-202. PubMed ID: 20392877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.